LONDON (Alliance News) - Akers Biosciences Inc said Wednesday that it had inked a distribution agreement for its PIFA Heparin/PF4 and PIFA PLUSS PF4 test kits with Medline Industries Inc.
Under the agreement Medline will begin marketing the tests over its network of hospitals and surgery centres across the US. The company's sales representatives will visit hospitals and market to multiple hospital departments, which Akers believes will increase the market penetration of the products.
The tests check for heparin-induced thrombocytopenia, which may occur if a patient develops an allergy to the blood thinning drug heparin.
No financial details of the agreement were disclosed.
Shares in Akers were trading up 17% at 315.00 pence Wednesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.


(Sharecast News) - Akers Biosciences appointed Howard Yeaton as chief executive on Monday as the company reached a settlement in its legal dispute wit...


(Sharecast News) - Akers Biosciences' losses burgeoned as second-quarter revenues were cut in half after softer sales of its flagship Heparin rapid as...


LONDON (Alliance News) - Akers Biosciences Inc on Tuesday said revenue grew in 2017, but its loss widened due to increased costs across the business.T...